Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
The advent of molecularly targeted agents is rapidly changing the management of metastatic renal cell carcinoma. A case in which surgical metastatectomy was used in the setting of dramatic but incomplete disease response to sunitinib is presented. Some of the issues complicating operative intervention in the setting of multitargeted tyrosine kinase inhibitors are discussed.
Neill
Mischel G
MG
Department of Urologic Oncology, University Health Network, Toronto, Ontario, Canada. mgneill@yahoo.com
Wei
Alice C
AC
Jewett
Michael A S
MA
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib